FDA approves Tafinlar + Mekinist combo for thyroid cancer

The FDA has approved the Tafinlar (dabrafenib) + Mekinist (trametinib) combo, by Switzerland-based Novartis, for patients with anaplastic thyroid cancer that cannot be removed by surgery. This is the first therapy approved by FDA for patients with this thyroid cancer type, which originates in a type of abnormal gene, BRAF V600E.

The Tafinlar-Mekinist was already approved in June 2017 for non-small-cell lung cancer with the same genetic defect.

(Source: Reuters)